HSP90AB1

Heat shock protein HSP 90-beta · P08238 · HSP90AB1 on Sugi Atlas →

120,839 patent compounds predicted against HSP90AB1, 71,410 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL184907 SCHEMBL184907 0.58 20/20
SCHEMBL156741 SCHEMBL156741 0.78 12/20
Quinocide Quinocide (SCHEMBL157174) 0.98 11/20
Primaquine Primaquine (SCHEMBL22207) 0.76 10/20
Primaquine Primaquine (SCHEMBL22208) 0.76 10/20
SCHEMBL138856 SCHEMBL138856 0.73 9/20
SCHEMBL191457 SCHEMBL191457 0.41 9/20
SCHEMBL140262 SCHEMBL140262 0.92 8/20
SCHEMBL140280 SCHEMBL140280 0.92 8/20
SCHEMBL138791 SCHEMBL138791 0.90 8/20
SCHEMBL140125 SCHEMBL140125 0.82 8/20
Pamaquine Pamaquine (SCHEMBL156942) 0.74 8/20
Primaquine Primaquine (SCHEMBL41096) 0.68 8/20
Primaquine Primaquine (SCHEMBL41097) 0.68 8/20
SCHEMBL138799 SCHEMBL138799 0.58 8/20
SCHEMBL202726 SCHEMBL202726 0.34 8/20
SCHEMBL141693 SCHEMBL141693 0.89 7/20
SCHEMBL154744 SCHEMBL154744 0.54 7/20
SCHEMBL94922 SCHEMBL94922 0.36 7/20
SCHEMBL144791 SCHEMBL144791 0.56 6/20

Clinical trials — most relevant to HSP90AB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease PHASE2COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) PHASE1/PHASE2COMPLETED
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer PHASE1/PHASE2COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies PHASE1WITHDRAWN
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors PHASE1COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors PHASE1COMPLETED
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis nanCOMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Chronic Heat Therapy for Improving Vascular Health nanCOMPLETED
Acute Passive Heating in Healthy Older Adults nanCOMPLETED
Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease nanCOMPLETED
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer nanUNKNOWN
Cardioprotective Benefit of Passive Heat Therapy in Higher-Level Spinal Cord Injury: Safety and Proof of Concept nanUNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition nanCOMPLETED
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSP90AB1 binder may also engage these)

ProteinNameSimilarity
Q04619 1.000 Q04619 →
Q5R710 1.000 Q5R710 →
P11501 1.000 P11501 →
P34058 1.000 P34058 →
P11499 1.000 P11499 →
P46633 1.000 P46633 →
P30947 1.000 P30947 →
Q9GKX7 1.000 Q9GKX7 →
Q4R4P1 1.000 Q4R4P1 →
Q76LV1 1.000 Q76LV1 →
Q9GKX8 1.000 Q9GKX8 →
A5A6K9 1.000 A5A6K9 →
HSP90AA1 Heat shock protein HSP 90-alpha 1.000 landscape →
Q76LV2 1.000 Q76LV2 →
O02192 1.000 O02192 →
Q6AZV1 1.000 Q6AZV1 →
Q4R4T5 1.000 Q4R4T5 →
O57521 1.000 O57521 →
P30946 1.000 P30946 →
O02705 1.000 O02705 →
P07901 1.000 P07901 →
P04809 1.000 P04809 →
P36181 1.000 P36181 →
P51819 1.000 P51819 →
Q7PT10 1.000 Q7PT10 →
P15108 1.000 P15108 →
P54651 1.000 P54651 →
P02828 1.000 P02828 →
Q9BLC5 1.000 Q9BLC5 →
P51818 1.000 P51818 →